Audentes Therapeutics, an Astellas company, is an AAV-based genetic medicines company focused on developing and commercializing innovative therapies that can offer transformative benefits to patients.

Innovative Therapies

In addition to our gene therapy portfolio targeting serious rare neuromuscular diseases, we are leveraging Astellas’ global resources, industry leadership in immune biology, and deep scientific expertise to expand our reach and deliver valuable new genetic medicines to patients around the world.

Courageous Patients

We see the patient community as our partners, collaborators, and teachers. We believe that their perspectives should be integrated throughout the drug development process from initiation of a clinical program to its completion and beyond.

Learn More

Bold Effort

The science of making AAV-based genetic medicines is complex. Our robust research laboratory and state-of-the-art vector manufacturing facility puts us at the forefront of developing innovative products. Our bold approach is driven by our commitment to bringing transformative treatments to patients living with serious rare neuromuscular diseases as rapidly as possible.

Our People

We take pride in our efforts to harness the transformative potential of AAV-based genetic medicines to improve the lives of patients around the world.



Audentes is different – we take time to understand our patient communities and weave that knowledge with our scientific insights to develop transformative therapies. Follow us on Facebook to share with us, stay updated and learn more.


What bold things can you expect from us next? Keep track of company announcements, by following us on Twitter!

Learn more about what we’re doing to become the leader in the development and commercialization of innovative genetic medicines to treat serious rare neuromuscular diseases, the people who make it great and the exciting job opportunities available by following us on LinkedIn.